Doxorubicin pharmacokinetics: The effect of abnormal liver biochemistry tests

Cancer Chemotherapy and Pharmacology

Volumn 42, Issue 3, 1998, Pages 229-234

  Twelves, Christopher J ^a,b   Dobbs, Nicola A ^a,c   Gillies, Helen C ^a   James, Christopher A ^a   Rubens, Robert D ^a   Harper, Peter G ^a  

^a GUY S HOSPITAL   (United Kingdom)

^b Garscube Estate ^*  (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Doxorubicin; ICG clearance; Liver biochemistry; Pharamacokinetics

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DOXORUBICIN; DOXORUBICINOL; INDOCYANINE GREEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER; MALE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; ASPARTATE AMINOTRANSFERASES; BILIRUBIN; DOXORUBICIN; FEMALE; HUMANS; INDICATORS AND REAGENTS; INDOCYANINE GREEN; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED;

EID: 0031816602     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050809     Document Type: Article

References (28)

1. Ackland SP, Ratain M, Vogelzang NJ, Choi KE, Ruane M, Sinckule JA (1989) Pharmacokinetics and pharmacodynamics of long-term continuous-infusion of doxorubicin. Clin pharmacol Ther 45: 340-347
2. Andrews PA, Brenner DH, Chou FTE, Kubo M, Bachur NR (1984) Facile and definitive determination of human adriamycin and daunorubicin metabolites by high pressure liquid chromatography. Drug Dispoj Metab 18: 152-156
3. Benjamin RS, Wiernik PH, Bachur NR (1973) Adriamycin chemotherapy efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule. Cancer 33: 19-27
4. Brenner DE, Wiernik PH, Wesley M, Bachur NR (1984) Acute doxorubicin toxicity. Relationship to pretreatment liver function, response, and pharmacokinetics in patients with acute nonlymphocytic leukemia. Cancer 53: 1042-1048
5. Caesar J, Shaldon S, Chiandussi L, Guevara L, Sherlock S (1967) The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci 21: 43-57
6. Camaggi CM, Strocchi E, Tamassia V, et al (1982) Pharmacokinetic studies of 4′-epi-Adriamycin in cancer patients with normal and impaired renal function and with hepatic metastases. Cancer Treat Rep 66: 1819-1824
7. Cammagi CM, Strocchi E, Comparsi R, Testoni F, Angelelli B, Pannuti F (1986) Biliary excretion and pharmacokinetics of 4′-epi-Adriamycin (epirubicin) in advanced cancer patients. Cancer Chemother Pharmacol 18: 47-50
8. Chan KK, Cheblowski RT, Tong M, Chen H-SG, Gross JF, Bateman JR (1980) Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res 40: 1263-1268
9. Chlebowski RT, Chan KK, Tong MJ, Weiner JM, Ryden VMJ, Bateman JR (1981) Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects. Cancer 48: 1088-1095
10. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
11. Dobbs NA, James CA (1987) Estimations of doxorubicin and doxorubicinol by high pressure liquid chromatography and advanced automated sample processor. J. Chromatogr 420: 184-188
12. Dobbs NA, Twelves CJ, Rizzi P, Warwick JD, Metevier EM, Williams R, Johnson PJ (1994) Epirubicin in hepatocellular carcinoma: a pharmacokinetic and clinical study. Cancer Chemother Pharmacol 34: 405-410
13. Dobbs NA, Twelves CJ, Gillies H, James CJ, Harper PG, Rubens RD (1995) Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 36: 473-476
14. Freedman LS, Workman P (1988) When can the infusion period be safely ignored in the estimation of pharmacokinetic parameters of drugs in humans? Cancer Chemother Pharmacol 22: 95-103
15. Frenay M, Milano G, Renee N. et al (1989) Pharmacokinetics of weekly low dose Adriamycin. Eur J Cancer Clin Oncol 25: 191-195
16. Johnson A, Woollard RC (1983) STRIPE: an interactive computer programme for the analysis of drug pharmacokinetics. J. Pharmacol Methods 9: 193-200
17. Johnson PJ, Dobbs N, Kalayci C, Aldous MC, Harper P, Metivier EM, Williams R (1992) Clinical efficacy and toxicity of standard dose adriamycin in hyperbilirubinaemic patients with hepatocellular carcinoma: relation to liver tests and pharmacokinetic parameters. Br J Cancer 65: 751-755
18. Kemeny MM, Sugarhaker PH, Smith TJ, Edwards BK, Shawker T, Vermess M, Jones AE (1982) A prospective analysis of laboratory tests and imaging studies to detect hepatic lesions. Ann Surg 195: 163-167
19. Lee YN, Chan KK, Harris PA, Cohen JL (1980) Distribution of adriamycin in cancer patients. Tissue uptakes, plasma concentration after iv and hepatic ia administration. Cancer 45: 2231-2239
20. Nielson NC (1963) Spectrophotometric determination of indocyanine green in plasma. Scand J Clin Invest 15: 613-621
21. O'Reilly SM, Richards MA, Rubens RD (1990) Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer 26: 574-577
22. Perrier D, Gibaldi M (1974) Clearance and biologic half-life as indices of intrinsic hepatic metabolism. J. Pharmacol Exp Ther 191: 17-24
23. Piscitelli SC, Rodvold KA, Rushing DA, Tewksbury DA (1993) Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. Clin Pharmacol Ther 53: 555-561
24. Preisler HD, Gessner T, Azurnia N. et al (1984) Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemia. Cancer Chemother Pharmacol 12: 125-130
25. Preiss R, Matthias M, Sohr R, Brockman B, Huller H (1987) Parmacokinetics of adriamycin, adrianiycinol, and antipyrine in patients with moderate tumor involvement of the liver. J Cancer Res Clin Oncol 113: 593-598
26. Robert J, Illiadis A, Hoerni B, Cano J-P, Durand M, Lagarde C (1982) Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. Eur J Cancer Clin Oncol 18: 739-745
27. Robert J, Vrignaud P, Nguyen-Ngoc T, Iliadis A, Mauriac L, Hurteloup P (1985) Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treat Rep 69: 633-640
28. Twelves CJ, Dobbs NA, Michael Y, Summers LA, Richards MA, Rubens RD (1992) Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests. Br J Cancer 66: 765-769